Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 11:00 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 3,459 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Metabolic Effects Clear all

Conditions: Pseudohypoparathyroidism Type 1A, Albright Hereditary Osteodystrophy, Pseudopseudohypoparathyroidism
Interventions: Neurocognitive and psychosocial testing; Behavioral
Lead sponsor: Connecticut Children's Medical Center; Other
Eligibility: 2 Months to 89 Years
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2030
U.S. locations: 1
States / cities: Hartford, Connecticut

Conditions: Systemic Lupus Erythematosus
Interventions: atorvastatin; Drug
Lead sponsor: The Center for Rheumatic Disease, Allergy, & Immunology; Other
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Obesity, Overweight
Interventions: AC2307, placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 273 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 18
States / cities: Birmingham, Alabama • Chandler, Arizona • Santa Rosa, California + 15 more

Conditions: End Stage Renal Disease, Hyperphosphatemia, Chronic Inflammation
Interventions: Ferric Citrate; Drug
Lead sponsor: Winthrop University Hospital; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Mineola, New York

Conditions: End Stage Renal Disease
Interventions: Etanercept, Placebo; Drug
Lead sponsor: Kaysen, George A., M.D., Ph.D.; Other
Eligibility: 18 Years to 80 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Weight Loss, BMD
Interventions: Weight Loss, Weight Maintenance; Behavioral
Lead sponsor: Rutgers University; Other
Eligibility: 50 Years to 72 Years · Male only
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Chronic Kidney Diseases
Interventions: Dietary education program; Behavioral
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 2
States / cities: Rochester, New York

Conditions: Head and Neck Neoplasms, Hearing Disorder, Hyperlipidemia
Interventions: Not listed
Lead sponsor: National Institute on Deafness and Other Communication Disorders (NIDCD); NIH
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 2
States / cities: Bethesda, Maryland

Conditions: Type 2 Diabetes
Interventions: Byetta (exenatide), Symlin (pramlintide); Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 12 Years to 21 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Alcohol Use Disorder, Alcohol Withdrawal, Alcohol Dependence, Ketosis
Interventions: Kenetik; Ketone Concentrate, Isocaloric dextrose placebo; Dietary Supplement
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 75 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania • Wernersville, Pennsylvania

Conditions: Type 2 Diabetes Mellitus
Interventions: Colesevelam hydrochloride, placebo; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Obesity, Metabolic Syndrome, Diabetes
Interventions: Recombinant methionyl human leptin; Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 80 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2010
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Obesity, Inflammation, Cardiovascular Disease, Oxidative Stress
Interventions: Grape in the form of freeze-dried whole grape powder, Grape powder placebo; Other
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Davis, California

Conditions: Overweight, Healthy
Interventions: Before meal, With Meal, After meal; Dietary Supplement
Lead sponsor: Clinical Nutrition Research Center, Illinois Institute of Technology; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Overweight
Interventions: benzoate containing test drinks, non sodium benzoate containing test drinks; Other
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 18 Years to 35 Years
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Overweight, Obesity
Interventions: Maridebart Cafraglutide, Moxifloxacin, Placebo for Maridebart Cafraglutide, Placebo for Moxifloxacin; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Daytona Beach, Florida • Dallas, Texas

Conditions: Pre-diabetes, Obesity
Interventions: Mirabegron 50 MG, Tadalafil 10 MG, Placebo; Drug
Lead sponsor: Philip Kern; Other
Eligibility: 35 Years to 65 Years
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Obesity
Interventions: Chewing gum, Water; Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 38 Years · Female only
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Complication of Hemodialysis, Cardiovascular Diseases
Interventions: sodium thiosulfate; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Metabolism and Nutrition Disorder, Obesity
Interventions: liraglutide, placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 846 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 67
States / cities: Vestavia Hills, Alabama • Peoria, Arizona • Jonesboro, Arkansas + 57 more

Conditions: Type 2 Diabetes
Interventions: Vitamin D, Placebo; Drug
Lead sponsor: University of Florida; Other
Eligibility: 30 Years to 65 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Healthy Subjects
Interventions: CapScan; Device
Lead sponsor: Envivo Bio Inc; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Mountain View, California

Conditions: Hypertension, Impaired Glucose Tolerance
Interventions: AR9281, Placebo; Drug
Lead sponsor: Arete Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 30
States / cities: Mobile, Alabama • Muscle Shoals, Alabama • Anaheim, California + 26 more

Conditions: Diabetes Mellitus
Interventions: OAP-189, placebo comparator; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 2
States / cities: Chula Vista, California • Miami Gardens, Florida

Search by objective public record fields.

Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments

Statins and Lupus: Effects of Statins on Clinical Lupus Parameters, Serological Markers and Toll-like Receptors

Study to Examine Safety, Tolerability and Effect on Body Weight of Subcutaneous AC2307 in Obese or Overweight Subjects

A Study of Ferric Citrate to Improve Inflammation and Lipid Levels

Safety and Efficacy Study of the Effect of Etanercept in Hemodialysis Patients

The Effect of Weight Loss on Bone in Men

Effects of a Whole-food, Plant-based Nutrition Program on BP and Potassium in Subjects With CKD

Hearing Loss and the Effects of Statin Drugs in People With Head and Neck Squamous Cell Carcinoma Treated With Cisplatin Chemoradiation

The Effect of Byetta and Symlin on Post-meal Meal Blood Sugar Levels in Children With Type 2 Diabetes

Effects of Ketone Supplementation on Acute Alcohol Withdrawal

Effects on Colesevelam HC1 (WelChol®) on Insulin Sensitivity in Subjects With Type 2 Diabetes Mellitus

Effects of Human Leptin Replacement

The Effects Grapes on Health Indices

Maximizing the Anti-inflammatory Effects of Strawberry Bioavailability

Effects of a Food Preservative on Glucose Homeostasis

Effect of Maridebart Cafraglutide on the Heart's Electrical Activity

The Effects of Mirabegron and Tadalafil on Glucose Tolerance in Prediabetics

The Effects of Gum Chewing on Energy Intake and Expenditure

Sodium Thiosulfate Treatment of Vascular Calcification in ESRD

Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE™ - Diabetes

Effects of Treating Vitamin D Deficiency in Poorly Controlled Type 2 Diabetes

Effect of Proton Pump Inhibitors on Gut Microbiota Composition and Metabolites in Healthy Subjects Using CapScan

Evaluation of Soluble Epoxide Hydrolase (s-EH) Inhibitor in Patients With Mild to Moderate Hypertension and Impaired Glucose Tolerance

Study Evaluating Safety, Tolerability, And Action Of OAP-189 In Subjects With Type 2 Diabetes On Metformin